Sort
10,766 grants matching “checkpoint inhibitor”
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
$435,586Markus Schober · New York University School Of Medicine · R01 · FY2025 · CA
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
$435,511Theresa M Busch · University Of Pennsylvania · R01 · FY2023 · CA
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
$435,511Theresa M Busch · University Of Pennsylvania · R01 · FY2022 · CA
Intrapleural immunotherapeutic nanoparticles for MPE treatment
$435,429Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2024 · CA
Project 3. Overcoming Melanoma Treatment Resistance with Cytokine Immunotherapy
$435,370Aaron Michael Ring · Yale University · P50 · FY2025 · CA
Project 2. Harnessing Epigenetic Regulation of Endogenous Retroelements in Melanoma
$435,370Qin Yan · Yale University · P50 · FY2025 · CA
Project 3: Demethylation of HPV-associated head and neck cancer to trigger APOBEC synthetic lethality and enhance immune response
$435,036Karen S Anderson · Yale University · P50 · FY2022 · DE
Race and ancestry as predictors of the tumor immune microenvironment and response to immunotherapy
$435,007Elad Ziv · University Of California, San Francisco · P20 · FY2025 · CA
Immune Checkpoints and HPV-associated Head and Neck Cancers
$435,000Sara Isabel Pai · Massachusetts General Hospital · R01 · FY2017 · DE
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
$434,992Elias Sayour · University Of Florida · R37 · FY2023 · CA
Deciphering MDSC function for GBM targeting
$434,936Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · NS
Tackling Treg mediated resistance to radiation and anti-PDL1 in HNSCCs
$434,700Sana D Karam · University Of Colorado Denver · R01 · FY2022 · DE
Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer
$434,696Rugang Zhang · Wistar Institute · R01 · FY2021 · CA
Targeting LSD1 to prevent therapy-induced transdifferentiation in BRAF mutant colorectal cancer
$434,552Heather M O'Hagan · Indiana University Indianapolis · R01 · FY2025 · CA
Targeting exosomal PDL1 to improve immunotherapy
$434,375Wei Guo · Wistar Institute · P50 · FY2021 · CA
Targeting PP4 to improve ovarian cancer response to immunotherapy
$434,357Marion Curtis · Mayo Clinic Arizona · R37 · FY2024 · CA
Targeting Epigenomic Regulators at the Replication Fork in PDAC
$434,301Gwen Lomberk · Medical College Of Wisconsin · R01 · FY2024 · CA
Role of Erbb3 kinase activity in colorectal tumorigenesis.
$434,298Zhenghe Wang · Case Western Reserve University · R01 · FY2021 · CA
Autophagy mediated immune stimulation by reovirus in KRAS mutated colorectal cancer
$433,953Radhashree Maitra · Yeshiva University · R15 · FY2022 · CA
Project 2: Combined CAR-T cell therapy
$433,764Gianpietro Dotti · Univ Of North Carolina Chapel Hill · P50 · FY2022 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$433,516Cesar M Castro · Massachusetts General Hospital · R01 · FY2023 · CA
Probing cellular, molecular and biomechanical barriers to immunotherapy in the tumor microenvironment with organotypic in vitro models of the tumor-lympho-immune interface
$433,439Melody A Swartz · University Of Chicago · R01 · FY2021 · CA
The unique roles of the GTP-binding/protein crosslinking enzyme transglutaminase-2 and signaling partners in aggressive cancers
$433,417Richard A. Cerione · Cornell University · R01 · FY2024 · CA
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
$433,366Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2023 · CA
Lung Cancer Vaccine
$433,293Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2024 · CA